NVCRN Stock Chart & Stats
$264.01
$0.00(0.00%)
At close: 4:00 PM EDT
$264.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$207.00 - $322.39
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$28.83B
Enterprise Value$1.54B
Total Cash (Recent Filing)$463.48M
Total Debt (Recent Filing)$231.55M
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Feb 25, 2027EPS Estimate
-4.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding116,445,840
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$402.82Price Target Upside52.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-23.12
Revenue Forecast (FY)$13.59B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong revenue expansion combined with roughly 76% gross margin indicates attractive product-level economics and growing commercial adoption. If maintained, this combination can support reinvestment, improve operating leverage, and provide a durable foundation for future profitability.
Raised Growth And Profitability GuidanceHigher revenue and adjusted EBITDA guidance signals improving execution and greater confidence in the commercial portfolio. Management also expects mid-to-high-70s gross margins and controlled R&D spending, which could support continued progress toward full-year profitability.
Expansion Of OptunePax In JapanJapanese approval expands OptunePax into a major international market and adds a new approved indication for NovoCure's platform. The approval broadens the addressable patient base, supports geographic diversification, and creates a pathway for future reimbursement-led adoption.
Bears Say
Ongoing Net LossesDespite improving losses, NovoCure has not yet demonstrated consistent earnings power. Continued net losses reduce internal capital generation and leave the business dependent on further revenue growth, cost discipline, and successful commercialization before profitability becomes durable.
Negative Free Cash FlowNegative free cash flow shows that the company is not yet self-funding its operations and investments. Even with burn moderating, sustained cash deficits can constrain flexibility and make progress toward cash-flow breakeven dependent on execution across products and markets.
OptunePax U.S. Launch DisruptionLimited access to prescribing practices is slowing OptunePax adoption in the U.S., one of NovoCure's important commercial markets. This disruption can delay patient growth, reimbursement momentum, and the product's contribution to the company's broader profitability transition.
NovoCure News
NVCRN FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $207.00 and its highest was $322.39 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $28.83B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 118 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Oct 29, 2026. The company reported -$1.699 earnings per share for the quarter, beating the consensus estimate of -$4.437 by $2.738.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -4.12.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 116,445,840 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$1.699 in its last earnings report, beating expectations of -$4.437. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in MX:NVCRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$402.82 (52.58% Upside)
$402.82 (52.58% Upside)
Blogger Sentiment
Bullish
MX:NVCRN Sentiment 75%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.74%
12-Months-Change
Fundamentals
Return on Equity
-35.81%
Trailing 12-Months
Asset Growth
-36.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCRN Company Deck
NVCRN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Management reported record patient levels and revenue, raised 2026 revenue and adjusted EBITDA guidance, delivered substantial year-over-year improvement in profitability metrics, and highlighted momentum in Optune Gio and Optune Lua in Japan. The principal negative issue was the U.S. OptunePax launch slowdown caused by practice disruption and limited access following the introduction of diraxonrasib, alongside a foreign exchange headwind and expected quarter-to-quarter EBITDA variability.View all MX:NVCRN earnings summariesNVCRN Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCRN Stock 12 Month Forecast
Average Price Target
$402.82
▲(52.58% Upside)
Technical Analysis
Accuray
―
Delcath Systems
―
Perspective Therapeutics
―
Sensus Healthcare
―
TriSalus Life Sciences
―